Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children

Current Opinion in HIV and AIDS

Volumn 7, Issue 4, 2012, Pages 305-316

  Kenny, Julia ^a,b   Musiime, Victor ^c   Judd, Ali ^a   Gibb, Diana ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

Author keywords

adverse drug reactions; birth registries; neonates; paediatrics HIV; pharmacovigilance; toxicity

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CONCENTRATION LOSS; DEPRESSION; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCRINE BONE DISEASE; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; GYNECOMASTIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERACTIVITY; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; HYPOPHOSPHATEMIA; INSOMNIA; INSULIN RESISTANCE; JAUNDICE; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TOXICITY; LOW BIRTH WEIGHT; MALARIA; MALNUTRITION; MOOD CHANGE; NAIL PIGMENTATION; NEURAL TUBE DEFECT; NEWBORN ANEMIA; NIGHTMARE; OSTEOPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; REGISTER; REVIEW; SEIZURE; SIDE EFFECT; SMALL FOR DATE INFANT; SUICIDAL IDEATION; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; HIV INFECTIONS; HUMANS; PHARMACOVIGILANCE;

EID: 84862563634     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328354da1d     Document Type: Review

References (98)

1. UNAIDS. Report on the global AIDS epidemic. 2010.
2. WHO UU. Global HIV/AIDS response. Epidemic update and health sector progress towards universal access. 30 November 2011. Report No.: Progress Report 2011.
3. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
4. El-Sadr WM, Lundgren JD, Neaton JD, et al., Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
5. Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010; 24:231-241.
6. Cotton M, Violari A, Gibb D, et al. Early ART followed by interruption Is safe and is associated with better outcomes than deferred ART in HIV infants: final results from the 6-year randomized CHER Trial, South Africa. 19th Conference on Retroviruses and Opportunistic Infections; Seattle; 2012.
7. Wamalwa D, Benki-Nugent S, Langat A, et al. Treatment Interruption in Infants following 24 Months of Empiric ART: Kenya. 19th Conference on Retroviruses and Opportunistic Infections; Seattle; 2012.
8. Nestorowicz A, Cameron S. Workshop report Key reports from the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Antivir Ther 2007; 12:987-998. (Pubitemid 47492570)
9. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007; 370:12-14. (Pubitemid 47017451)
10. Marcus KA, Sorbello A, Truffa M, et al. Current advances in Pharmacovigilance in USA and Europe: meeting the challenges of safety monitoring in HIV. Curr Opin HIV AIDS, 2012; 7:292-298.
11. De Vries TW, van Roon EN. Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. Arch Dis Child 2010; 95:1023-1026.
12. WHO and The Global Fund. Pharmacovigilance Toolkit. 2012. Ref Type: Online Source.
13. Bakare N, Edwards IR, Stergachis A, et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Med 2011; 8:e1001054.
14. Huff-Rousselle M, Simooya O, Kabwe V, et al. Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond. Global Public Health 2007; 2:184-203. (Pubitemid 46736530)
15. Jaquet A, Djima MM, Coffie P, et al. Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Co te dIvoire. Pharmacoepidemiol Drug Safety 2011; 20:1303-1310.
16. Ruud KW, Srinivas SC, Toverud EL. Addressing gaps in pharmacovigilance practices in the antiretroviral therapy program in the Eastern Cape Province, South Africa. Res Soc Admin Pharm 2010; 6:345-353.
17. Miller V, Nwokike J. Pharmacovigilance and Global HIV/AIDS. Curr Opin HIV and AIDS. 2012; 7:299-305.
18. Hankin CD, Newell ML, Tookey DP. Long-term follow-up of uninfected children born to HIV-infected women and exposed to antiretroviral therapy: survey of parents and health professionals views. AIDS Care 2007; 19:482-486. (Pubitemid 46598744)
19. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924. (Pubitemid 47580389)
20. Bergsjo P, Mlay J, Lie RT, et al. A medical birth registry at Kilimanjaro Christian Medical Centre. East Afr J Public Health 2007; 4:1-4.
21. Kurewa EN, Kandawasvika GQ, Mhlanga F, et al. Realities and challenges of a five year follow up of mother and child pairs on a PMTCT Program in Zimbabwe. Open AIDS J 2011; 5:51-58.
22. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-489. (Pubitemid 352005822)
23. Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry Interim Report 01 January 1989 to 31 July 2011. 2012.
24. European Medicines Agency. Paediatric investigation plans, waivers and modifications. 2012. Ref Type: Online Source.
25. Division of AIDS, Bethesda MNIoH. Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; clarification August 2009. 2009.
26. Baroncelli S, Pinnetti C, Genovese O, et al. Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. J Med Virol 2011; 83:551-556.
27. Vigano A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259-1266.
28. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012. doi: 10.1097/QAD.0b013e328352d135. http://journals.lww.com/ aidsonline/Abstract/ publishahead/Safety-of-tenofovir-use-during-pregnancy- early.98971.aspx. [Accessed 16 May 2012].
29. Gibb D, Kizito H, Russell E, et al. Health outcomes of infants born to HIVinfected mothers receiving long-term antiretroviral therapy with and without tenofovir in the DART trial 2004-9. PLoS Med 2012; 9:e1001217. doi:10.1371/journal.pmed.1001217.
30. Ford N, Calmy A, Mofensen L. Safety of efavirenz in first-trimester of pregnancy: anupdated systematic reviewandmeta-analysis. AIDS2011;25:2301-2304.
31. Ekouevi DK, Coffie PA, Ouattara E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS databases, Abidjan, Cote dIvoire. J Acquir Immune Defic Syndr 2011; 56:183-187.
32. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506-514.
33. Beckerman K, Albano J, Cohan D, et al. Exposure to combination antiretroviral regimens containing protease inhibitors during pregnancy and prevalence of low birth weight/preterm delivery among women with low preexisting risk: a stratifiedanalysis of10082prospective live births, TheAntiretroviral Pregnancy Registry, 1989-2010. 6th International AIDS Society (IAS), Rome; 2011.
34. Mandelbrot L, Mazy F, Floch-Tudal C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol 2011; 157:18-21.
35. Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr 2011; 56:428-436.
36. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic shortterm toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr Infect Dis J 2010; 29:376-379.
37. McKoy JM, Bennett CL, Scheetz MH, et al. Hepatotoxicity associated with long-versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf 2009; 32:147-158.
38. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 379:221-228.
39. McArthur MA, Kalu SU, Foulks AR, et al. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J 2009; 28:1127-1129.
40. Watts DH, Huang S, Culnane M, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med 2011; 39:163-170.
41. Broom J, Sowden D. Premature labour precipitated by highly active antiretroviral therapy: an adverse reaction in a newly diagnosed HIV-positive patient. Sex Health 2011; 8:436-438.
42. Van der Merwe K, Hoffman R, Black V, et al. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc 2011; 14:42.
43. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089. (Pubitemid 29452821)
44. Landreau-Mascaro A, Barret B, Mayaux MJ, et al. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359:583-584. (Pubitemid 34178445)
45. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114:e598-e603. (Pubitemid 41647668)
46. Tovo PA, Chiapello N, Gabiano C, et al. Case report Zidovudine administration during pregnancy and mitochondrial disease in the offspring. Antivir Ther 2005; 10:697-699. (Pubitemid 41376847)
47. European Collaborative Study Group. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV infected women. J Acquired Immune Deficiency Syndr 2003; 32:380-387.
48. Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-1 exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000; 918:222-235.
49. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002; 30:200-215. (Pubitemid 34664418)
50. Boxwell D, Cao K, Lewis L, et al. Neonatal toxicity of Kaletra oral solution-LPV, ethanol, or propylene glycol? 18th Conference on Retroviruses and Opportunistic Infections, Boston; 2011.
51. Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011; 306:70-78.
52. Benhammou V, Warszawski J, Bellec S, et al. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS 2008; 22:2165-2177.
53. Hankin C, Lyall H, Peckham C, Tookey P. Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data. AIDS 2007; 21:867-869. (Pubitemid 46573159)
54. Fielder J, Rambiki K. Occurrence of stavudine-induced lactic acidosis in 3 members of an African family. J Int Assoc Physicians AIDS Care 2010; 9:236-239.
55. Nahirya-Ntege P, Musiime V, Naidoo B, et al. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J 2011; 30:535-537.
56. Bouazza N, Urien S, Hirt D, et al. Population pharmacokinetics of tenofovir in HIV-1 infected pediatric patients. J Acquir Immune Defic Syndr 2011; 58:283-288.
57. Mulenga V, Cook A, Walker AS, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination baby pills in Zambia: a randomized controlled trial. Clin Infect Dis 2010; 51:1081-1089.
58. Strehlau R, Martens L, Coovadia A, et al. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J 2011; 30:1001-1003.
59. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6 to 18 years): week 24 primary analysis of the phase II PIANO study [abstract TULBPE027], 6th IAS Conference on HIV pathogenesis, treatment and prevention, Rome. 2011; pp, 17-20.
60. Nso AP, Larru B, Bellon JM, et al. HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations. J Adolesc Health 2011; 48:100-102.
61. Thuret I, Chaix ML, Tamalet C, et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009; 23:2364-2366.
62. Briz V, Leoá n-Leal JA, Palladino C, et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J 2012; 31:273-277.
63. Wiznia A, Samson P, Acosta E. Safety and efficacy of raltegravir (RAL) in pediatric HIV infection. Preliminary analysis from IMPAACT P1066. 2009.
64. Lee JSF, Calmy A, Andrieux-Meyer I, Ford N. Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV/AIDS (Auckland, NZ) 2012; 4:5-15.
65. Patel P, Song I, Borland J, et al. Pharmacokinetics of a dolutegravir pediatric granule formulation in healthy adult subjects. 19th Conference on Retroviruses and Opportunistic Infections; 2012.
66. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010; 24:525-534.
67. WHO. Antiretroviral Therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach 2010 revision. http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html. [Accessed 27 April 2012]
68. Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10:591-613.
69. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of onceversus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10:239-246. (Pubitemid 41151030)
70. Valerius NH. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-36 months. Antivir Ther 2010; 15:297-305.
71. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008; 42:387-396. (Pubitemid 351429604)
72. Orkin C, Wang J, Bergin C, et al. An epidemiologic study to determine the prevalence of the HLA-B 5701 allele among HIV-positive patients in Europe. Pharmacogenet Genomics 2010; 20:307-314.
73. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. 2009. WHO, UNAIDS, UNICEF. Ref Type: Online Source.
74. Alam N, Cortina-Borja M, Goetghebuer T, et al. Body fat abnormality in HIVinfected children and adolescents living in Europe: prevalence and risk factors Fat abnormality in children. Journal of Acquired Immune Deficiency Syndromes 2012; 59:314-324.
75. Shiau S, Arpadi S, Strehlau R, et al. Lipodystrophy syndrome in young HIVinfected children in South Africa who initiate antiretroviral treatment before 2 years of age. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; Seattle; 2012.
76. Were TP. Prevalence and factors associated with lipodystrophy among children on HAART at the paediatric infectious diseases clinic, Mulago Hospital. 2009.
77. Innes S, Cotton M, Haubrich R, et al. High prevalence of objectively verified clinical lipoatrophy in prepubertal children is associated with stavudine the clock Is ticking: sub-Saharan Africa. 19th Conference on Retroviruses and Opportunistic Infections; Seattle; 2012.
78. Venter WD, Innes S, Cotton M. Low-dose stavudine trials: a public health priority for developing countries. South Afr J HIV Med 2012; 13:20-21.
79. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40:161-168. (Pubitemid 41395714)
80. Dzwonek AB, Lawson MS, Cole TJ, Novelli V. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:121-123. (Pubitemid 44306499)
81. Aurpibul L, Puthanakit T, Taejaroenkul S, et al. Recovery from lipodystrophy in human immunodeficiency virus-infected children after substitution of stavudine with zidovudine in a nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. The Pediatric infectious disease Journal 2012; 31: 384-388.
82. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007; 21:947-955. (Pubitemid 46684326)
83. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
84. Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289-1298.
85. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV infected patients on highly active antiretroviral therapy: a population based nationwide cohort study. HIV Med 2010; 11:130-136.
86. Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84-91.
87. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28.
88. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53:62-69.
89. Satchell CS, Cotter AG, OConnor EF, et al. Platelet function and HIV: a case-control study. AIDS 2010; 24:649-657.
90. De Pablo C, Orden S, Apostolova N, et al. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS 2010; 24:1259-1266.
91. Baum PD, Kosikova G, Galkina S, et al. Abacavir, a competitive inhibitor of soluble guanylyl cyclase, increases platelet reactivity. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco; 2010.
92. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-2027.
93. The SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIVinfected patients. AIDS 2008; 22:F17-F24.
94. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2009; 28:204-209.
95. Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Invest 2011; 31: 407-415.
96. Reid A, Stöhr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46:1271-1281. (Pubitemid 351589914)
97. Palumbo P, Violari A, Lindsey J, et al. NVP-vs LPV/r-based ART among HIV infants in resource-limited settings: the IMPAACT P1060 Trial. 18th Conference on Retroviruses and Opportunistic Infections; Boston; 2011.
98. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS 2011; 25:2279-2287.